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Background: Glucocorticoids have been proven to be effective in the therapy of recurrent airway obstruction
(RAO) in horses via systemic as well as local (inhalative) administration. Elective analysis of the effects of this drug
on bronchoconstriction in viable lung tissue offers an insight into the mechanism of action of the inflammatory
cascade occurring during RAO which is still unclear. The mechanism of action of steroids in treatment of RAO is
thought to be induced through classical genomic pathways. We aimed at electively studying the effects of the
glucocorticoid beclomethasone dipropionate on equine precision-cut lung slices (PCLS).
PCLS were used to analyze ex-vivo effects of beclomethasone on inhibiting bronchoconstriction in the horse. The
inhibiting effect was measured through instillation of a known mediator of inflammation and bronchoconstriction,
leukotriene C4. For this, the accessory lobes of 13 horses subjected to euthanasia for reasons unrelated to the
respiratory apparatus were used to obtain viable lung slices.
Results: After 30 minutes of PCLS incubation, beclomethasone showed to significantly inhibit the contraction of
the bronchioles after instillation with leukotriene C4. The EC50 values of the two contraction curves (LTC4 with and
without BDP) differed significantly from each other (p = 0.002). The possibility of a non-genomic rapid mechanism
of action seems likely since transcriptional activities require a longer lag period.
Conclusions: In human neuroendocrinology, high levels of glucocorticoids have been proven to function via a
non-genomic mechanism of membrane receptors. The concentration of beclomethasone used on the lung slices
in our study can be considered as high. This allows speculation about similar rapid non-genomic mechanisms of
high-dosage inhaled glucocorticoids in the lower airways of horses. However, further assessment on a molecular
basis is needed to confirm this.
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The exact interactions of the single inflammatory media-
tors within the inflammatory cascade taking place during
recurrent airway obstruction (RAO) in the horse are still
unclear. Ex-vivo precision-cut lung slices (PCLS) from ter-
minal airways of the horse offer a unique condition where* Correspondence: maria.fugazzola@gmail.com
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reproduction in any medium, provided the orthe interaction of single inflammatory agents (i.e. bronch-
oconstrictors) and anti-inflammatory agents (i.e. broncho-
dilators) can be observed without multifactorial influence
as occurs in vivo. This may be useful to further under-
stand the pathogenesis of RAO. The aim of the study was
to take a first step to analyse the interaction of two sub-
stances involved in bronchoconstriction and bronchodila-
tion in healthy pulmonary tissue of 13 horses.
Synthetic glucocorticoids are recognized to be effective in
the treatment of RAO in horses and have been widely usedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Their beneficial effects are thought to be mainly achieved
through their potent anti-inflammatory properties. They in-
activate NF-kB, blocking transcription of genes coding for
pro-inflammatory cytokines, up-regulate and increase the
sensitivity of β2-adrenoceptors and reduce production of
pro-inflammatory eicosanoids [1]. Their mechanism of ac-
tion is mainly genomic with lag periods ranging from at
least four to several hours or even days the manifest action
of drug-induced response takes place [2-4].
Inhalation of glucocorticoids has become a good alter-
native to systemic administration in chronic obstructive
airway diseases where high local concentration of the
drug, lower dosage and the low risk of unwanted systemic
side effects represent the major advantages of way of ad-
ministration [5,6]. Beclomethasone dipropionate (BDP) is
a widely administered inhaled corticosteroid in equine
practice [7,8], although in vivo studies have shown that
the marked improvement of clinical signs of airway ob-
struction after administration of low-dose inhaled beclo-
methasone was not accompanied by a decrease in airway
inflammatory cells or a suppression of transcription fac-
tors NF-kB and AP-1 DNA-binding activity [9].
In the respiratory apparatus, the small airways are
most affected by inflammatory processes of RAO
[8,10,11] and represent the major target tissue for anti-
inflammatory agents and bronchodilators.
In the past, leukotrienes have been shown to mimic
many of the pathophysiological processes in allergic air-
way disease [12,13] and since leukotriene C4 is renowned
for its potent bronchoconstricting action, it was chosen
as bronchoconstrictor in our study.
Scientific investigations on the possible role of the
cysteinyl leukotrienes in RAO have been reported in re-
cent years. Lavoie et al. could not demonstrate improved
lung function in horses with RAO after administration
of a leukotriene D4 antagonist [14]. A more recent study
suggested that there is increased leukotriene B4 and C4
production in airways of horses affected with RAO
which may contribute to infiltration of neutrophils into
the lungs and the sustained inflammation associated
with RAO [15]. In an earlier study, the inhalative admin-
istration of LTD4 and LTB4 to healthy horses caused
bronchoconstriction and neutrophil accumulation re-
spectively [16]. Specifically, ex vivo LTC4 caused marked
bronchoconstriction in equine PCLS which could be
antagonized by the receptor antagonist MK-571 [17]. A
hyper-reactivity of the bronchioles of RAO-affected
horses in comparison to healthy horses was also demon-
strated [17]. To date, no in vivo studies on effects of
LTC4 have been reported.
We aimed at examining the effects of directly instilled
beclomethasone on viable equine terminal airways to de-
termine its capacity of inhibiting bronchoconstriction.Methods
Animals
13 horses (8 geldings, 4 mares, 1 stallion; 16 ± 6 years of
age [mean ± SD]; 500 ± 90 kg of body weight) which were
to be euthanized due to conditions unrelated to this
study or pulmonary disease were used for this study.
After a general clinical examination, a specific examin-
ation of the respiratory apparatus consisting of ausculta-
tion, percussion, bronchoscopy, TBS-analysis and blood
gas analysis was performed to exclude respiratory dis-
ease. Seven of the horses had received non-steroidal
analgesics and antibiotic therapy related to the primary
problem in the period preceding our study. After sed-
ation (Detomidine, 0,02 mg/kg iv), euthanasia was per-
formed using an overdose of pentobarbital.
Experimental procedures
The method for production of PCLS was congruous
with the one validated in previous studies [18-20] and
will therefore be described summarily.
Immediately post mortem, the accessory lobe was
removed with a cutting wire loop which was placed
around the base of the lobe after opening the thorax and
subsequently chilled to 4°C on ice, decreasing metabolic
activity in the tissue without losing viability. In order to
harden the lung tissue, the lobe was filled with a 1,5%
low melting point agarose solution (type VII, Sigma-
Aldrich Chemie, Germany) [21]. The agarose was
enriched with cell culture medium (RPMI-1640
Medium, Biochrom AG Berlin, Germany) to provide nu-
trition to the tissue throughout the cutting procedures.
Subsequently, precision cut lung slices with a diameter
of 8 mm and a thickness of 400 μm were obtained from
the lung tissue with a microtome (Krumdieck Tissue
Slicer Model MD 4000, Alabama Research and Develop-
ment). At the centre of each slice, the integrity, i.e. the
presence of a terminal bronchiolus which was orientated
perpendicular to the cut surface was condition of selec-
tion. After bedding the obtained PCLS in RPMI culture
medium, viability was checked for each slice by contrac-
tion with metacholine (10-5 mol/l). A minimum of 50%
lumen reduction was chosen as selection criterion. Vi-
able slices were then washed with RPMI medium three
times and incubated for 30 minutes to allow dilatation.
Absence of pre-contraction was assessed by comparing
initial values of bronchiolar lumen diameter with those
after the reopening phase before the first contraction
with leukotriene C4 was performed.
The concentration of LTC4 used for bronchoconstric-
tion was based on an earlier study on PCLS where
CysLT1 antagonists had been examined [17].
After checking quality and viability of the slices, LTC4
was applied to 6 PCLS of each horse to establish the in-
dividual reactivity of the different horses’ tissue. The
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for each application (every two minutes), starting with
10-15 mol/l up to 10-8 mol/l. A visual example of this
procedure is shown in the Additional file 1. The effects
of the bronchoconstrictor LTC4 were recorded through
digital photography two minutes after every increase of
concentration. After rinsing, 3 PCLS were incubated for
30 minutes with BDP at the concentration of 10-5 mol/l
and 3 PCLS remained untreated. After incubation and
dilatation of all 6 PCLS, another contraction series with
LTC4 was performed.
The effects of the bronchoconstrictor LTC4 with and with-
out beclomethasone dipropionate were recorded through
digital photography after every increase of concentration.
As a final step, the PCLS were again rinsed and incu-
bated for 30 to 40 minutes in order to dilate. A further
contraction with 10-8 mol/l LTC4 was performed to as-
sure viability of the slices throughout the procedures. If
a 50% lumen reduction was not achieved at this point,
slices where excluded from statistical analysis.
The photographed lumen area of the bronchioles after
each concentration increase was measured three times
manually with a digitalising tablet (TrustW) and the aver-
age value was used. This value was quantified withSlice A Slice 
Slice A Slice
Figure 1 Comparison between BDP-treated and untreated PCLS, and
slices (slice A and B). Bottom row: after instillation with LTC4, with slice A p
Magnification 100x (ZeissW Axiostar Microscope Universal Digicam Adapterpercentage digital measurement (“Scion Image Version
Beta 4.0.2”) and statistically analysed afterwards.
Statistics
In order to compare reactivity of PCLS to LTC4 in our
study to results of earlier studies, an EC50 was calculated.
EC50 was defined as the concentration at which the PCLS
contracted their lumen to 50% of the original surface area.
Where a minimum of 50% lumen reduction was not
reached, the EC50 concentration was defined as>−8 mmol/l.
The effect of beclomethasone was compared with un-
treated control slices by comparing the EC50 values of the
two groups using the Wilcoxon test. In order to obtain
one data point per increasing LTC4 concentration, the
average of 3 PCLS measurements per horse was used.
A p-value < 0.05 was regarded significant.
The software used for statistic evaluation was Graph
Pad Prism 5.
Results and discussion
From each accessory lobe, 40 to 60 viable slices could be
obtained. After exposure to LTC4, the PCLS treated with
BDP for 30 minutes showed less contraction than the un-
treated slices. As shown in Figure 1, at the appliedB before instillation of LTC4
 B after instillation of LTC4
their reaction to instillation of LTC4 (10
-8mol/l). Top row: untreated
reviously treated with BDP at 10-5 mol/l, slice B untreated.
).
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inhibitory effect on LTC4-induced bronchoconstriction.
Whilst lumen reduction in the untreated PCLS started
at a concentration of 10-13 mol/l LTC4, the beclometha-
sone group only started to react at a concentration of
10-11 mol/l LTC4. Moreover, the treated PCLS showed a
lower degree of contraction than the untreated slices even
at the highest concentration of LTC4. The calculated
EC50 values of the two contraction series (LTC4 with
and without BDP) differed significantly from each other
(p= 0.002) (Figure 2). In the BDP-treated group a right
shift of the concentration-effect curve, i.e. the increase of
LTC4 concentration needed to induce a 50% bronchial
lumen reduction, was obvious in PCLS of all but one
horse when compared to the untreated group (Figure 3).
The calculated EC50 for LTC4 during the first contrac-
tion series of all included PCLS was 2 x 10-10 mol/l
whilst the calculated EC50 for LTC4 after 30 minutes in-
cubation with BDP (10-5 mol/l) was 3 x 10-9 mol/l.
The well-investigated genomic anti-inflammatory ef-

















Figure 2 Calculated EC50 values for each horse before and after treat
calculated EC50 values of the two contraction series (LTC4 with and withou
indicates the negative power of 10 (mol/l) as the expression of the LTC4 cocytoplasmic receptor which, when activated, migrates to
the nucleus. The activated receptor can interact with
transcription factors (i.e. NF-kappaB, AP-1) inhibiting
the synthesis of pro-inflammatory proteins (i.e. cyto-
kines, COX-2). This trans-repressive activity explains
most of the anti-inflammatory effects of glucocorticoids
[22]. Since this mechanism is dependent on protein syn-
thesis, the manifest action of the glucocorticoid takes
place only after the characteristic lag period which
ranges from at least four to several hours or even days
[2-4,23].
In our study, incubation periods of 30 minutes with
BDP seem too short for transcriptional procedures so it
is likely that the inhibiting effect was mediated by a non-
genomic mechanism of action which occurs instantan-
eously after exposure or within a very short latency
period [2-4,24,25]. The non-genomic receptors directly
activate various second messengers (e.g. Ca++-dependant
protein kinases, cAMP) [26,27] which regulate specific
biological actions within the cells such as bronchodila-
tion, secretion, absorption etc. A controversy regarding,002
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t BDP) differed significantly from each other (p = 0.002). The number
































Figure 3 Graphical representation of inhibitory effect of beclomethasone dipropionate on LTC4-induced bronchoconstriction. Indication
of the bronchial lumen (given in % of initial value) in dependency of LTC4 concentrations (given in 10
-x mol/l). Data shown are means ± SD of 13
horses.
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transcription-independent cellular responses to steroids
is presently attracting considerable scientific interest
[2,4,28,29]. There is strong evidence that classic recep-
tors belonging to the nuclear receptor superfamily medi-
ate non-genomic steroid effects in some cases [30]. In
the human brain, the rapid non-genomic effect of corti-
coids seems to depend on classical mineralocorticoid
receptors which are accessible from the outside of the
plasma membrane and display a 10-fold lower affinity
for corticosterone than the nuclear version involved in
neuroprotection. Consequently, this type of receptor
seems to play an important role while corticosteroid
levels are high, i.e. during the initial phase of the stress
response [31].
In our case, the concentration of BDP (10-5 mol/l) used
for our study was based on Chanoine´s studies on rat
lungs where intratracheal administration of the same con-
centration of BDP was used to assess pharmacokinetics
[32]. Considering the short distance of diffusion and the
small amount of lung tissue in PCLS treated with each ap-
plication of BDP, 10-5 mol/l may be considered a high dos-
age. Since this dosage might be difficult to achieve in vivo,
lower dosages should be assessed in following studies in
order to confirm clinical relevance of these findings.
Another consideration is that a classic genomic mech-
anism would prevent bronchoconstriction by inhibiting
at a higher level of the inflammatory signal cascade.
Thus, final products such as leukotriene would not be
produced. Since, in our study, the inflammatory medi-
ator was directly instilled on the PCLS, a genomic mech-
anism of action could not occur; instead, a direct action
of the glucocorticoid is most likely.
The pharmacological action of beclomethasone on LTC4
catabolism in transformed human bronchial epithelial cell
lines accelerates the degradation of LTC4 into less active
(less contractile) LTE4 and LTD4 [33]. This mechanism isunlikely the same as in our study since increase of LTC4 ca-
tabolism was observed only after 2-day BDP incubation
period of the cells, suggesting new protein synthesis.
In vivo BDP has proven to be effective in the therapy of
RAO in horses [34,35]. The first signs of clinical im-
provement could only be seen after four days of treat-
ment. Although this would indicate a complex trans-
repressive mechanism of action, Couteil et al. could not
show a decrease in pro-inflammatory transcription fac-
tors (NF-kappaB, AP-1) in the BALF despite clinical signs
improving significantly [9]. These findings are in line
with our results and suggest that clinical improvement
(in our study inhibition of bronchoconstriction) was
achieved through a fast-acting non-genomic mechanism.
Conclusion
In this study, the mechanisms of action through which
inhibition of bronchoconstriction was achieved were not
investigated. There is evidence for a rapid and non-
genomic reduction of intracellular [Ca2+] induced by al-
dosterone in human bronchial epithelium [36]. This
could give reason to speculate about an inhibiting action
of BDP on bronchoconstriction in PCLS through rapid
calcium reduction in smooth muscle cells. In conclusion,
we may say that further investigation is needed to under-
stand the exact mechanism of action with which BDP at
a high dosage inhibits bronchoconstriction in terminal
airways through a non-genomic pathway.
Additional file
Additional file 1: Contraction of bronchiolus after instillation of
10-13 mol/l LTC4.
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